RASAZILECT rasagiline mesilate 1 mg tablets, blister

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

rasagiline mesilate, Quantity: 1.56 mg

Disponibbli minn:

Arrotex Pharmaceuticals Pty Ltd

Għamla farmaċewtika:

Tablet, uncoated

Kompożizzjoni:

Excipient Ingredients: purified talc; microcrystalline cellulose; maize starch; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

10, 30

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Sommarju tal-prodott:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2018-01-23